Abstract Number: 1536 • 2013 ACR/ARHP Annual Meeting
Do Patients With Ankylosing Spondylitis Have An Excess Prevalence Of Chronic Widespread PAIN?: Results From The Scotland and Ireland Registry For Ankylosing Spondylitis (SIRAS) and The Musician Study
Background/Purpose: To determine whether there is an excess prevalence of chronic widespread body pain (CWP) in patients with Ankylosing spondylitis (AS). Methods: Patients were…Abstract Number: 1537 • 2013 ACR/ARHP Annual Meeting
Primary & Subsequent Orthopedic Surgeries More Common In Juvenile Vs. Adult-Onset Ankylosing Spondylitis
Background/Purpose: Patients experiencing ankylosing spondylitis (AS) symptoms ²16 years-of-age are classified as juvenile-onset AS (JoAS), whilst those ³17 years adult-onset AS (AoAS). We compared JoAS…Abstract Number: 1538 • 2013 ACR/ARHP Annual Meeting
The Age At Onset Of Symptoms Influence The Clinical Expression Of The Disease In Patients With Ankylosing Spondylitis
Background/Purpose: The onset of symptoms before 10 years and after 40 years is uncommon in patients with ankylosing spondylitis (AS). Some authors have found specific…Abstract Number: 1539 • 2013 ACR/ARHP Annual Meeting
Inflammation In The Posterior Elements Of The Spine Is Infrequent In Patients With Recent Onset Axial Spondyloarthritis, Especially If No Inflammation In The Vertebral Bodies Is Observed
Background/Purpose: There is evidence that in almost all patients with longstanding and active ankylosing spondylitis (AS) inflammatory lesions in the posterior elements are as frequent…Abstract Number: 1540 • 2013 ACR/ARHP Annual Meeting
Sustained Clinical Remission In Patients With Non-Radiographic Axial Spondyloarthritis After Two Years Of Adalimumab Treatment
Background/Purpose: Adalimumab (ADA) is currently approved in the EU for the treatment of severe non-radiographic axial spondyloarthritis (nr-axSpA), in patients (pts) with an elevated CRP…Abstract Number: 1500 • 2013 ACR/ARHP Annual Meeting
Use Of B Lymphocyte Stimulator Inhibitor Belimumab May Be Associated With a Decrease In the Serum Concentration Of Endothelial Growth Factor In Patients With Primary Sjögren’s Syndrome
Background/Purpose: , Primary Sjögren's Syndrome (pSjS) is a systemic autoimmune inflammatory disease that primarily affects the lacrimal and salivary glands and is associated with B…Abstract Number: 1501 • 2013 ACR/ARHP Annual Meeting
Umbilical Cord Mesenchymal Stem Cells Inhibit The Generation Of T Follicular Helper Cell In Sjogren’s Syndrome
Background/Purpose: The immune suppressive properties of mesenchymal stem cells (MSC) have garnered increasing attention over past decades. Human umbilical cord-derived MSC (UC-MSC) share similar immunosuppressive…Abstract Number: 1502 • 2013 ACR/ARHP Annual Meeting
Antibodies To Anti-Type -3 Muscarinic Acetylcholine Receptor Are Highly Prevalent To Rabbits Immunized With 4-Hydroxy-2-Noneal-Modified and 60-Kda Ro
Background/Purpose: In Sjörgen’s Syndrome, an autoimmune disease, the lacrimal and salivary glands are the primarily affected glands. Previous studies have proposed autoantibodies that target type-3…Abstract Number: 1503 • 2013 ACR/ARHP Annual Meeting
The Suppressive Ability Of Altered Peptide Ligands To M3R Reactive T Cells In M3R Induced Autoimmune Sialadenitis
Background/Purpose: Previous studies have shown that Rag1-/- mice transferred with splenocytes of M3 muscarinic acetylcoline receptor (M3R)-/- mice immunized with M3R peptides mixture (three N-terminal…Abstract Number: 1504 • 2013 ACR/ARHP Annual Meeting
Anti-Inflammation Effect Of Peroxisome Proliferator-Activated Receptor-ã (PPAR-ã) In Non-Obese Diabetic Mice With Sjogren’s Syndrome
Background/Purpose: To investigate the anti-inflammation effect of peroxisome proliferator-activated receptor-γ (PPAR-γ) in non-obese diabetic mice (NOD mice) with sjogren`s syndrome.Methods: Twenty 8-weeks-old female NOD mice were randomly divided into…Abstract Number: 1505 • 2013 ACR/ARHP Annual Meeting
Evaluation Of a Case Ascertainment Tool For Ankylosing Spondylitis and Axial Spondylarthritis Among All Referrals To General Rheumatology Clinics
Background/Purpose: Several strategies for distinguishing Ankylosing Spondylitis (AS) and Axial Spondylarthritis (axSpA) from other conditions have been proposed but have only been studied in the…Abstract Number: 1506 • 2013 ACR/ARHP Annual Meeting
Total Hip Replacement Outcomes in Ankylosing Spondylitis
Background/Purpose: Historically, outcomes for total hip replacement (THR) in ankylosing spondylitis (AS) patients were poor, but contemporary outcomes are not well described. We analyzed two-year…Abstract Number: 1507 • 2013 ACR/ARHP Annual Meeting
Infection Risk in Ankylosing Spondylitis: Results From a Longitudinal Observational Cohort
Background/Purpose: Long term data on infection risk in ankylosing spondylitis (AS) are sparse and derived mainly from RCTs. Anti-TNF therapy is increasingly used in AS,…Abstract Number: 1508 • 2013 ACR/ARHP Annual Meeting
How Well Are The Assessment Of Spondyloarthritis International Society (ASAS) / Outcome Measures In Rheumatology (OMERACT) Core Outcome Sets For Ankylosing Spondylitis Implemented In Randomized Clinical Trials? A Systematic Literature Review
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) has selected a core set of variables to include as standardized endpoints in clinical trials and clinical…Abstract Number: 1509 • 2013 ACR/ARHP Annual Meeting
Immunogenicity, Adalimumab Levels and Clinical Response In Ankylosing Spondylitis Patients During 24 Weeks Of Follow-Up
Background/Purpose: Immunogenicity influences adalimumab levels and therefore clinical response in patients with rheumatic diseases. Objectives: To study the relation between clinical response, adalimumab levels and…
ACR Meeting Abstracts